FemGuard + Balance TM
Natural health product licensed in Canada
- Licence holder
- Designs for Health
- NPN or DIN-HM
- 80051105
- Status
- Inactive licence
- Licence date
- 23 May 2014
- Revision date
- 4 June 2015
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Dose déclarée au-delà d'une limite
Vitamine B6: up to 7.5 mg a day according to the dosing instructions published by Health Canada (1 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 2 mg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Conditions légales
Actaea racemosa L.: Seuls les extraits aqueux et hydro-alcooliques de titre faible (30 %) sont admis. La portion journalière recommandée ne doit pas conduire à une ingestion de glycosides de triterpène (calculés comme 27-déoxyactéine) supérieure à 3 mg.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Vitex agnus-castus L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Brassica oleracea L.: L'étiquetage doit comporter un avertissement recommandant aux personnes ayant une hypothyroïdie ou un traitement de la thyroïde de consulter leur médecin.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| 3,3'-méthylènebis-1H-indole Source : 3,3'-diindolylméthane | 25 mg | Not calculated |
| Magnésium Source : Malate de dimagnésium | 12.5 mg | 12,500 µg |
| Actaea racemosa Source : Racine et rhizome Potency : 2.5 % Triterpene glycosides | 25 mg | Not calculated |
| Vitex agnus-castus Source : Fruit Potency : 0.5 % Agnuside | 25 mg | Not calculated |
| Brassica oleracea var. italica Source : Graine(s) Potency : 10 % Glucoraphanin | 25 mg | Not calculated |
| trans-Resvératrol Source : Reynoutria Japonica - racine | 5 mg | Not calculated |
| Vitamine B6 Source : 5-phosphate de pyridoxal | 7.5 mg | 7,500 µg |
| Vitamine B6 Source : Chlorhydrate de pyridoxine | 7.5 mg | 7,500 µg |
| Vitis vinifera Source : Graine(s) Potency : 95 % Proanthocyanidins | 6.25 mg | Not calculated |
| Calcium Source : Malate de dicalcium | 23 mg | 23,000 µg |
| Calcium Source : Diglycinate de calcium | 23 mg | 23,000 µg |
| Curcuma longa Source : Rhizome Potency : 95 % Curcuminoids | 12.5 mg | Not calculated |
| Rosmarinus officinalis Source : Feuille Potency : 7 % dl-Camphor | Not specified | Not calculated |
| Rosmarinus officinalis Source : Feuille | 12.5 mg | Not calculated |
Non-medicinal ingredients
Cellulose microcristalline, Stéarate de magnésium, Dioxyde de silicium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Capsule | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
A source of antioxidants for the maintenance of good health. Helps relieve symptoms associated with menopause. Calcium intake, when combined with sufficient vitamin D, a healthy diet, and regular exercise, may reduce the risk of developing osteoporosis. Helps in the development and maintenance of bones. Helps the body to metabolize carbohydrates, fats and proteins.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80051105
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Actaea racemosa
Read the warning, when it applies and the studies cited
Black Cohosh - Actaea Racemosa
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver disorder or develop symptoms of liver trouble (EMA 2018, 2007; Lynch et al. 2006; Mills et al. 2006; Cohen et al. 2004; NIH 2004).
6 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Contraindications
Do not use if you are pregnant (Brinker 2010; Hoffmann 2003; Tilgner 1999).
3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
- Vitex agnus-castus
Read the warning, when it applies and the studies cited
CHASTE TREE - VITEX AGNUS-CASTUS
Route of administration: Oral (WHO 2009; Bradley 2006; Mills and Bone 2000)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking hormone-containing medications such as progesterone preparations, oral contraceptives or hormone replacement therapy (Brinker 2010; WHO 2009; Bradley 2006).
3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Contraindications
Do not use if you are pregnant, breastfeeding or attempting to conceive unless you have consulted with a health care practitioner/health care provider/health care professional/doctor/physician (EMA 2018; Najib et al. 2022; Brinker 2010; WHO 2009; Dugoua et al. 2008; ESCOP 2003; Blumenthal 2000; Mills and Bone 2000).
8 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
- Curcuma longa
Read the warning, when it applies and the studies cited
TURMERIC - CURCUMA LONGA - Oral
Route of administration: Oral (ESCOP 2003; Blumenthal et al. 2000)
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (ESCOP 2003; Brinker 2001; McGuffin et al. 1997).
3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver or biliary disorder (HC 2025; EMA 2018; Brinker 2010; ESCOP 2003; McGuffin et al. 1997).
5 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications (HC 2025).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience any new symptoms including yellowing of the eyes or skin, dark urine, nausea, vomiting, stomach pain (HC 2025).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: All uses except for Source of antioxidants and Hepatoprotectant.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 26 September 2025
Turmeric -CURCUMA LONGA - Topical
Cautions and warnings
For external use only.
When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.
Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.
Contraindications
Do not use on deep or puncture wounds, animal bites or serious burns.
- Rosmarinus officinalis
Read the warning, when it applies and the studies cited
ROSEMARY – ROSMARINUS OFFICINALIS Oral
Route of administration: Oral (ESCOP 2003)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Contraindications
Do not use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000).
4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Health Canada monograph dated 29 May 2026
ROSEMARY - ROSMARINUS OFFICINALIS Topical
Route of administration: Topical (ESCOP 2003)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000).
4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have large open wounds, skin lesions, feverish conditions, acute inflammation, severe circulatory disorders or hypertension (ESCOP 2003).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Barnes et al. 2007; ESCOP 2003).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.